Coya Therapeutics’ (COYA) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report sent to investors on Monday morning,Benzinga reports. The brokerage currently has a $15.00 target price on the stock.

A number of other brokerages have also recently issued reports on COYA. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, February 2nd. Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $4.45 on Monday. Coya Therapeutics has a fifty-two week low of $3.94 and a fifty-two week high of $7.75. The stock’s 50-day moving average is $4.72 and its two-hundred day moving average is $5.55. The firm has a market cap of $104.40 million, a P/E ratio of -3.50 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The company had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%. On average, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $4,640,000. AWM Investment Company Inc. acquired a new stake in shares of Coya Therapeutics in the fourth quarter worth $4,205,000. Private Management Group Inc. bought a new position in Coya Therapeutics during the fourth quarter worth $1,626,000. Marshall Wace LLP increased its position in Coya Therapeutics by 438.8% during the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after acquiring an additional 183,533 shares during the period. Finally, Dauntless Investment Group LLC raised its stake in Coya Therapeutics by 199.5% during the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.